CONCORD DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.81 INR | -2.50% |
|
-4.74% | -40.04% |
| Sales 2022 | 590M 7.08M 566M | Sales 2023 | 521M 6.24M 499M | Capitalization | 256M 3.06M 245M |
|---|---|---|---|---|---|
| Net income 2022 | 15M 180K 14.37M | Net income 2023 | 9M 108K 8.62M | EV / Sales 2022 | 0.71 x |
| Net Debt 2022 | 164M 1.96M 157M | Net Debt 2023 | 169M 2.02M 162M | EV / Sales 2023 | 0.81 x |
| P/E ratio 2022 |
15.9
x | P/E ratio 2023 |
25.9
x | Employees | 185 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 31.04% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.50% | ||
| 1 week | -4.74% | ||
| Current month | -4.43% | ||
| 1 month | -5.24% | ||
| 3 months | -23.30% | ||
| 6 months | +8.71% | ||
| Current year | -40.04% |
1 week
35.70
38.49
1 month
35.3440.00
Current year
33.4957.88
1 year
25.5661.50
3 years
19.5061.50
5 years
11.6861.50
10 years
11.6891.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 03/04/03 | |
| Director of Finance/CFO | 34 | 09/06/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 03/04/03 | |
| Director/Board Member | 63 | 23/04/95 | |
| Director of Finance/CFO | 34 | 09/06/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/05/24 | 35.81 | -2.50% | 7,507 |
| 06/05/24 | 36.73 | -1.37% | 5,186 |
| 03/05/24 | 37.24 | +0.49% | 9,577 |
| 02/05/24 | 37.06 | -1.09% | 4,289 |
| 30/04/24 | 37.47 | -0.32% | 8,044 |
Delayed Quote Bombay S.E., May 07, 2024 at 11:00 am
More quotes
Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.
Sector
Pharmaceuticals
Calendar
27/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.04% | 4.4M | |
| +33.43% | 690B | |
| +26.43% | 546B | |
| -5.12% | 358B | |
| +19.59% | 323B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B |
- Stock Market
- Equities
- CONCORD6 Stock
